CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden … [Read more…]

TOKYO & SUNNYVALE, Calif.–(BUSINESS WIRE)–#IVD–Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley … [Read more…]

BANGALORE, India–(BUSINESS WIRE)–The Eurofins Consumer Product Testing network of laboratories in India recently unveiled its expanded, state-of-the-art facilities in Hongasandra, Bangalore. This strategic investment doubles the Bangalore laboratory’s footprint and offers enhanced capabilities, enabling a significant leap in compliance and performance testing tailored to the evolving needs of India’s textile, apparel, footwear, and leather goods … [Read more…]

SHANGHAI & INDIANAPOLIS–(BUSINESS WIRE)–Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in its first-in-human Phase I clinical trial (NCT06801236) of ACE-232, a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant … [Read more…]

BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About … [Read more…]

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 … [Read more…]

Global eClinical Connect events kick off this week, leading up to annual ENGAGE conference in the fall, as company continues to build innovative avenues to empower life sciences leaders BOSTON–(BUSINESS WIRE)–eClinical Solutions LLC, a global provider of digital clinical software and services, today announced its participation in several June events, including the DIA 2025 Global … [Read more…]

RENO, Nev.–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nevada (“Molina”), today announced over $700,000 in grants to the University of Nevada, Reno School of Medicine (“UNR Med”) in support of six programs focused on enhancing access to care, especially in areas of Nevada with shortages of health professionals. Health workforce shortages … [Read more…]

Broad coverage, inclusive of all previously covered Signatera indications AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian … [Read more…]

SHANGHAI–(BUSINESS WIRE)–Pacific Prime, a global health insurance intermediary group in international health insurance and employee benefits solutions, is proud to announce that two children with heart disease, financially assisted by Pacific Prime Group’s Shanghai office in China, successfully underwent surgeries in May 2025! The two children are a 3-year-old girl from Guizhou and an 11-year-old … [Read more…]